Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated

Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, talks about what clinical data has been presented at ASH could change the way penta-refractory multiple myeloma patients are treated

Tags: ASH Conference CoverageMultiple Myeloma

Published: 07 December 2018

Recent Videos

video

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...

video

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...

video

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...

video

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...

video

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...

video

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...

video

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...

video

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...

video

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...

video

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...

Related Videos

video-image

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

video-image

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

video-image

Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies

video-image

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

video-image

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

video-image

Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data

video-image

Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL

video-image

Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019

video-image

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019

video-image

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

video-image

Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality

video-image

Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL